Harmony Biosciences Holdings, Inc. (HRMY) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
HRMY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
HRMY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 77.2% | 24.0% | 18.3% |
| 2024 | 78.1% | 26.7% | 20.4% |
| 2023 | 79.2% | 33.0% | 22.1% |
| 2022 | 80.9% | 27.4% | 41.4% |
| 2021 | 81.8% | 28.7% | 11.3% |
Download Data
Export HRMY earnings history in CSV or JSON format
Free sign-in required to download data
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Overview
As of May 6, 2026, Harmony Biosciences Holdings, Inc. (HRMY) reported trailing twelve-month net income of $159M, reflecting +8.0% year-over-year growth. The company earned $2.70 per diluted share over the past four quarters, with a net profit margin of 18.3%.
Looking at the long-term picture, HRMY's historical earnings data spans multiple years. The company achieved its highest annual net income of $181M in fiscal 2022.
Harmony Biosciences Holdings, Inc. maintains industry-leading profitability with a gross margin of 77.2%, operating margin of 24.0%, and net margin of 18.3%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including JAZZ ($29M net income, -8.3% margin), AVPT ($35M net income, 8.4% margin), AXSM (-$188M net income, -28.7% margin), HRMY has outperformed on profitability metrics. Compare HRMY vs JAZZ →
HRMY Earnings vs Peers
Earnings metrics vs comparable public companies
HRMY Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $159M | +9.1% | $208M | $2.71 | 18.3% | 24.0% |
| 2024 | $145M | +12.9% | $191M | $2.51 | 20.4% | 26.7% |
| 2023 | $129M | -29.0% | $192M | $2.13 | 22.1% | 33.0% |
| 2022 | $181M | +424.5% | $120M | $2.97 | 41.4% | 27.4% |
| 2021 | $35M | +193.6% | $88M | $0.58 | 11.3% | 28.7% |
| 2020 | -$37M | +75.7% | $17M | $-1.10 | -23.1% | 10.6% |
| 2019 | -$152M | -280.9% | -$146M | $-2.94 | -2535.1% | -2433.8% |
| 2018 | -$40M | - | -$41M | $-1.42 | - | - |
See HRMY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HRMY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HRMY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHRMY — Frequently Asked Questions
Quick answers to the most common questions about buying HRMY stock.
Is HRMY growing earnings?
HRMY EPS stands at $2.70, with +8.0% growth matching the 5-year CAGR of N/A. TTM net income is $159M. Earnings trajectory remains consistent.
What are HRMY's profit margins?
Harmony Biosciences Holdings, Inc. net margin is +18.3%, with operating margin at +24.0%. Above-average margins indicate pricing power.
How consistent are HRMY's earnings?
HRMY earnings data spans 2018-2025. The current earnings trend is +8.0% YoY. Historical data enables comparison across business cycles.